Standard Adjuvant Endocrine Therapy

Phase 3Small molecule

Standard Adjuvant Endocrine Therapy is one of 34 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

AdjuvantActive, not recruiting

Breast CancerPhase 3

Active, not recruiting

AdjuvantPhase 3

Active, not recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Standard Adjuvant Endocrine Therapy

Eli Lilly

Phase 3

1 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Duragesic

CCephalon

Preclinical

1 5

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 6

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 7

Tianeptine

Pfizer

Preclinical

1 8

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Adjuvant

NCT02513394

Q2 2029

Phase 3Active, not recruiting

Breast Cancer

NCT03155997

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT03155997·5,637 enrolled

Adjuvant1 trial

PALbociclib CoLlaborative Adjuvant Study

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 3·NCT02513394·5,796 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard Adjuvant Endocrine Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard Adjuvant Endocrine Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard Adjuvant Endocrine Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Standard Adjuvant Endocrine Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Breast Cancer1 trial

Adjuvant1 trial

References

Drug Info

Quick Facts

Related News